🤖 Introducing Owkin K: A community of specialized AI agents. Their mission? To work with our data scientists on decoding the complexities of the immune system. We are excited to continue our ambition for the future of drug discovery, development and diagnostics. 🚀 Watch the video to find out how Owkin will use agentic AI in the future. #ai #agenticai
Owkin
Biotechnology Research
New York, NY 40,149 followers
We use AI to find the right treatment for every patient.
About us
Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).
- Website
-
https://www.owkin.com
External link for Owkin
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2016
- Specialties
- artificial intelligence, omics technology, oncology, drug discovery, medical research, biomedical images, real-world data, real world evidence, radiology, clinical data, federated learning, covariate adjustment, clinical tools, digital pathology, healthcare, diagnostic solutions, biomarkers, precision medicine, and data science
Locations
Employees at Owkin
-
Jean-Philippe Vert
Chief R&D at Owkin / Co-founder at Bioptimus / Use AI to unravel biology and find the right treatment for every patient
-
Helen Burns
Freelance Resourcing Director | Talent Acquisition Leader | Coach delivering impact through change | Flow Game Host
-
Michaël Auffret
-
Rodney Hawkins
Updates
-
🏖️ Summer is in full swing, and we couldn’t be happier. To celebrate these sun-soaked months, we’re excited to share our Owkinautes' summer adventures. They're off on exciting journeys around the world, and we're eager to follow along! In two weeks, our Chief Marketing Officer, Darius Meadon, will head to Bali to complete his 200-hour Yoga Teacher Training. He plans to use his new skills to start community yoga classes in London for people with mental health issues, those recovering from injury and long term illness, and older/vulnerable people affected by isolation. 🧘💛 #OwkinSummer
-
-
Today, our latest machine learning (ML) research on the application of representation learning to RNA-seq data was published in Nature Scientific Reports. Using pan-cancer datasets (TCGA and DepMap), we assessed various models for their power to predict survival and gene essentiality, and explored the impact of various ML design choices, on the performance of the learned representations. 📕 Check out our open access publication to learn more about the results of this research: https://lnkd.in/ebp9XV72 #AI #representationlearning #RNAseq #cancerresearch
-
-
We are excited to share our latest research introducing our new AI model, MISO (Multiscale Integration of Spatial Omics), available today as a preprint on bioRxiv & medRxiv. Trained on a new unpublished dataset of 72 10X Genomics Visium samples with corresponding digital pathology images, MISO enables near single-cell-resolution, spatially-resolved gene expression prediction from H&E-stained slides. With spatial transcriptomics remaining challenging to use routinely, our model represents a novel approach for augmenting multimodal datasets and scale up integration of spatial transcriptomics data with tumor morphology. 📑 Read our pre-print at https://lnkd.in/gsvdKk7p #AI #spatialomics
-
-
Accelerate oncology breakthroughs and improve patient outcomes with the world's largest spatial omics dataset for oncology, MOSAIC research 🧬 We’re harnessing the power of AI and spatial omics to assist oncologists and pathologists in advancing drug discovery and enhancing target identification. Schedule your demo here to learn more: https://lnkd.in/ecMupPaf
-
Diving deeper into this morning’s "From Slides to Devices” blog, Dr. Frederik Deman discusses ZAS - Ziekenhuis aan de Stroom's two ongoing projects with Owkin around sharing data and digitized slides. “Owkin has helped us identify very small artifacts in our slides, thanks to this information, we can now improve the quality of our slides.” Read Dr. Deman’s testimonial https://lnkd.in/eYmXwAsN
-
-
📕 Introducing the second blog of our series, "From Slides to Devices," where we discuss the importance of data in building AI diagnostics. We deep dived into how Owkin’s MSIntuitⓇ CRC diagnostic works with whole slide images, and how it provides a digital pathology prescreen approach to pathologists and oncologists. The power of AI diagnostics comes from data, not just algorithms. In machine learning, AI analyzes patterns in complex images and associates them with labels, as pathologists do with tissue samples. These labels help group patients by characteristics or identify specific objects, such as tumors. Read the blog: https://lnkd.in/eagChYCP
-
-
AI in medicine helps deliver more accurate diagnoses, personalized treatments, and a transformed patient-doctor relationship. Our Chief Diagnostics Officer, Meriem Sefta, discussed the turning point of AI in healthcare on Converteo's podcast "Changement d'époque en cours" 🇫🇷 with Marjorie Paillon and Laurent Nicolas-Guennoc. 🎧 Listen to the podcast: https://lnkd.in/gWPPHjw8
-
-
RlapsRisk® BC can predict the risk of recurrence for ER /HER2- breast cancer patients at the time of diagnosis. Professor Catherine Guettier, Head of Pathology at Hopital Bicètre Greater Paris University Hospitals - AP-HP, showcases how they’re using digitized slides and CaloPix®, Tribun’s Health IMS system, to support pathologists and oncologists in the future, making more informed treatment decisions and improving patient outcomes. Learn more about RlapsRisk® BC: https://lnkd.in/eYYc3tZr
-
Identifying new promising therapeutic targets is traditionally slow and resource-intensive, involving laborious literature review and extraction of data from past clinical trials. In our latest blog, we discuss how we’re integrating large language models (LLMs) into TargetMATCH, our AI-powered target discovery engine. This integration not only enhances our team’s expertise but also fosters collaboration between data scientists and biologists, significantly accelerating our time to results. 📑 Read more here: https://lnkd.in/eQxRz2qi Davide Mantiero, PhD Antonin Dauvin Eric Durand Thea Backlar Adi Ravia Valentine Perrin Thomas Chaigneau #AI #LLMs #drugdiscovery